BMS Confirms Fatal Outcome in Multiple Sclerosis CAR-T Trial Amid Autoimmune Safety Scrutiny

Key points

• BMS reported a patient death in a Phase 1 trial for its autoimmune CAR-T therapy targeting multiple sclerosis.
• The patient experienced unresolved motor symptoms, received a potent immunosuppressant, and subsequently developed septic pneumonia before dying.
• BMS stated it had an answer for a safety signal observed in a separate lupus trial, though specific details were not fully disclosed in the summary.
• The death adds to broader safety concerns regarding CAR-T therapies for autoimmune conditions, following similar issues at Novartis.
• BMS had previously paused studies in September after observing transient inflammatory events during routine surveillance.

Background

The CAR-T therapy landscape for autoimmune diseases has faced significant scrutiny in 2026. In September, BMS paused studies after observing inflammatory events, while Novartis disclosed three patient deaths in its autoimmune trials. Competitors like Adicet Bio and Kyverna Therapeutics have reported favorable safety profiles in their own trials, distinguishing their therapies from the autologous approaches facing these setbacks. BMS has also had recent successes in other CAR-T areas, such as its Phase 2 trial for multiple myeloma, but the autoimmune sector remains volatile due to these safety signals.

How outlets are covering it

Endpoints News reported the death and BMS's response regarding the lupus trial safety signal, framing it as a direct answer to ongoing questions. STAT provided more clinical detail, specifying that the patient developed septic pneumonia after receiving an immunosuppressant for unresolved motor symptoms. STAT also contextualized the event within the broader industry trend, noting that Novartis had disclosed three deaths in September. Both outlets agree on the fact of the death but differ in the level of clinical detail provided; STAT offers the specific cause of death and treatment sequence, while Endpoints focuses on the corporate response and the lupus trial issue.

Why it matters

This death highlights the ongoing safety challenges in developing CAR-T therapies for autoimmune conditions, a field that has seen multiple trial pauses and fatalities in 2026. It may impact investor confidence in BMS's autoimmune pipeline and could influence regulatory scrutiny of similar therapies. The contrast with competitors like Adicet Bio and Kyverna, who have reported safer profiles, may shift market attention toward alternative approaches in this therapeutic area.

What to watch

BMS will likely face further scrutiny from regulators and investors regarding the safety of its autoimmune CAR-T program. The company may need to provide more detailed data on the lupus trial safety signal and the multiple sclerosis trial outcomes. Competitors with favorable safety profiles may gain a competitive advantage in the autoimmune CAR-T space. Investors will watch for any further safety events or trial pauses in the sector.